Filter Results
Clinical Studies
Results filtered:Study status:
Open
Closed for Enrollment
Open
-
Genetic and Molecular basis of Lipodystrophy syndromes
Rochester, Minn.
The purpose of this study is to understand the genetic basis for lipodystrophy. Subjects with lipodystrophy experience fat loss and the study aims to understand the genetic and molecular mechanisms leading to this.
Closed for Enrollment
-
A 12-Month Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Patients With Partial Lipodystrophy (METRE-PL)
Rochester, Minn.
The purpose of this study is to evaluate the effectiveness of daily subcutaneous (SC) metreleptin treatment in subjects with familial partial lipodystrophy (FPLD), and to assess the effect of metreleptin on fasting blood glucose (FBG).
-
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia Undergoing Lipid Apheresis Therapy (ODYSSEY ESCAPE)
Rochester, Minn.
This is a randomized, double-blind, placebo-controlled, parallel-group study to evaluate the effect of alirocumab in comparison with placebo on the frequency of LDL apheresis treatments in patients with HeFH undergoing LDL apheresis therapy.
-
A Randomized, Double-Blind, Placebo-Controlled, With an Open Label Extension, Phase 2/3 Study of ISIS 304801 Administered Subcutaneously to Patients With Familial Partial Lipodystrophy
Rochester, Minn.
The purpose of this study is to evaluate the efficacy and safety of volanesorsen (IONIS-APOCIIIRx) given for 52 weeks in patients with Familial Partial Lipodystrophy. Patients will then be allowed to continue in a 2 year Open Label Extension of the study.
-
A Randomized, Double-Blinded, Placebo-Controlled Phase IIa Study to Assess the Efficacy and Safety of a Novel AstraZeneca Compound in Subjects with Non-Alcoholic Steatohepatitis (NASH) or Non-Alcoholic Fatty Liver Disease (NAFLD)
Rochester, Minn.
The purpose of this study is to assess a new drug to decrease liver fat in subjects with Non-Alcoholic Steatohepatitis or Non-Alcoholic Fatty Liver Disease.
-
Genetic and Metabolic Basis of Familial Partial Lipodystrophy (FPL)
Rochester, Minn.
The purpose of this study is to find the gene mutations and metabolism dysfunctions that appear to cause the physical disorders of people who have Familial Partial Lipodystrophy.
.